Shares of FibroGen, Inc (NASDAQ:FGEN) have been assigned a consensus rating of “Buy” from the nine research firms that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, six have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $66.60.

A number of research analysts have recently issued reports on the company. William Blair reaffirmed an “outperform” rating on shares of FibroGen in a research note on Wednesday, August 9th. Goldman Sachs Group, Inc. (The) lowered shares of FibroGen from a “buy” rating to a “neutral” rating and set a $31.00 target price for the company. in a report on Friday, July 21st. BidaskClub lowered shares of FibroGen from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Leerink Swann reiterated an “outperform” rating and set a $82.00 target price (up from $52.00) on shares of FibroGen in a report on Tuesday, August 8th. Finally, Citigroup Inc. increased their target price on shares of FibroGen from $48.00 to $65.00 and gave the stock a “top pick” rating in a report on Tuesday, August 8th.

Get FibroGen Inc alerts:

In other news, VP Pat Cotroneo sold 95,000 shares of the stock in a transaction dated Tuesday, August 8th. The shares were sold at an average price of $50.61, for a total transaction of $4,807,950.00. Following the completion of the sale, the vice president now directly owns 173,366 shares in the company, valued at $8,774,053.26. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider K Peony Yu sold 37,500 shares of the stock in a transaction dated Tuesday, August 8th. The stock was sold at an average price of $50.58, for a total transaction of $1,896,750.00. Following the sale, the insider now owns 236,507 shares of the company’s stock, valued at $11,962,524.06. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 477,938 shares of company stock valued at $17,570,645. 14.90% of the stock is currently owned by company insiders.

Hedge funds have recently modified their holdings of the company. State Street Corp raised its stake in shares of FibroGen by 16.4% in the second quarter. State Street Corp now owns 1,763,387 shares of the biopharmaceutical company’s stock valued at $56,962,000 after buying an additional 248,922 shares during the period. Cornerstone Capital Management Holdings LLC. raised its stake in shares of FibroGen by 1.7% in the second quarter. Cornerstone Capital Management Holdings LLC. now owns 29,090 shares of the biopharmaceutical company’s stock valued at $939,000 after buying an additional 474 shares during the period. Janus Henderson Group PLC bought a new stake in shares of FibroGen during the second quarter valued at approximately $45,633,000. Hillhouse Capital Management Ltd. raised its stake in shares of FibroGen by 75.0% in the second quarter. Hillhouse Capital Management Ltd. now owns 1,750,000 shares of the biopharmaceutical company’s stock valued at $56,525,000 after buying an additional 750,000 shares during the period. Finally, Tudor Investment Corp ET AL raised its stake in shares of FibroGen by 7.1% in the second quarter. Tudor Investment Corp ET AL now owns 12,095 shares of the biopharmaceutical company’s stock valued at $391,000 after buying an additional 799 shares during the period. Institutional investors and hedge funds own 43.03% of the company’s stock.

FibroGen (NASDAQ:FGEN) opened at 44.05 on Tuesday. The firm’s 50-day moving average price is $35.25 and its 200 day moving average price is $28.50. The firm’s market capitalization is $3.14 billion. FibroGen has a one year low of $15.60 and a one year high of $51.70.

FibroGen (NASDAQ:FGEN) last announced its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.47) by $0.01. FibroGen had a negative net margin of 105.59% and a negative return on equity of 64.42%. The company had revenue of $29 million for the quarter, compared to the consensus estimate of $34.80 million. On average, equities analysts anticipate that FibroGen will post ($1.82) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “FibroGen, Inc (FGEN) Receives Consensus Rating of “Buy” from Brokerages” was published by American Banking News and is owned by of American Banking News. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/08/15/fibrogen-inc-fgen-receives-consensus-rating-of-buy-from-brokerages.html.

FibroGen Company Profile

FibroGen, Inc is a science-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.